Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of VRS-859 in Patients With Type 2 Diabetes

被引：0
|
作者：
Cleland, Jeffrey L.
Aronson, Ronnie
Humphriss, Eric
Shore, Camille
Zhou, Rong
Kipnes, Mark S.
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1105-P
引用
收藏
页码：A285 / A285
页数：1
相关论文
共 50 条
  • [1] Safety, pharmacokinetics, and pharmacodynamics of a single subcutaneous dose of VRS-859 in patients with type 2 diabetes
    Cleland, J.
    Aronson, R.
    Humphriss, E.
    Shore, C. R.
    Bright, G.
    Zhou, R.
    Kipnes, M. S.
    DIABETOLOGIA, 2012, 55 : S338 - S339
  • [2] A Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Sub cutaneous Administration of VRS-859 in Patients with Type 2 Diabetes Mellitus
    Cleland, Jeffrey L.
    Shore, Camille R.
    Kipnes, Mark S.
    DIABETES, 2011, 60 : A278 - A279
  • [3] A placebo controlled single ascending dose Phase 1 for safety, tolerability, pharmacokinetics and pharmacodynamics of VRS-859 in patients with T2DM
    Cleland, J. L.
    Shore, C. R.
    Kipnes, M. S.
    DIABETOLOGIA, 2011, 54 : S318 - S318
  • [4] Pharmacokinetics, pharmacodynamics, safety and tolerability of single dose exenatide in very elderly patients (≥75 years) with type 2 diabetes
    Linnebjerg, H.
    Kothare, P. A.
    Seger, M.
    Mitchell, M.
    DIABETOLOGIA, 2009, 52 : S308 - S308
  • [5] Multiple dose safety, tolerability, and Pharmacokinetics/Pharmacodynamics of exenatide in Japanese patients with type 2 diabetes
    Kothare, Prajakti
    Linnebjerg, Helle
    Isaka, Yoshitaka
    Uenaka, Kazunori
    Yamamura, Ayuko
    Shigeta, Hirofumi
    Yeo, Kwee Poo
    Teng, Choo Hua
    De La Apena, Amparo
    Mace, Kenneth
    Fineman, Mark
    Sakata, Yukikuni
    Irie, Shin
    DIABETES, 2006, 55 : A461 - A461
  • [6] Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    Kolterman, OG
    Kim, DD
    Shen, L
    Ruggles, JA
    Nielsen, LL
    Fineman, MS
    Baron, AD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (02) : 173 - 181
  • [7] Exenatide in adolescent patients with type 2 diabetes: Pharmacokinetics, pharmacodynamics, safety, and
    Malloy, Jaret
    Guan, Xuesong
    Kothare, Prajakti.
    Capparelli, Edmund
    Fineman, Mark
    DIABETES, 2008, 57 : A145 - A145
  • [8] A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes
    Fraser, Iain P.
    Neufeld, Naomi D.
    Fox, Larry A.
    Kipnes, Mark S.
    Miller, Tracie L.
    Zeitler, Philip S.
    Rodriguez, Henry
    Gilmartin, Jocelyn H.
    Lee, Susan J.
    Patterson, Jaclyn K.
    Li, Xiujiang S.
    Maganti, Lata
    Luo, Wen-Lin
    Tatosian, Daniel A.
    Stoch, S. Aubrey
    PEDIATRIC DIABETES, 2019, 20 (01) : 48 - 56
  • [9] Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
    Hiroaki Iijima
    Takayuki Kifuji
    Nobuko Maruyama
    Nobuya Inagaki
    Advances in Therapy, 2015, 32 : 768 - 782
  • [10] Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
    Iijima, Hiroaki
    Kifuji, Takayuki
    Maruyama, Nobuko
    Inagaki, Nobuya
    ADVANCES IN THERAPY, 2015, 32 (08) : 768 - 782
12345